Remimazolam

How it works

Benefits

Dosage & preparation

Risks & contraindications

Comparisons

Highlighted claims

• Remimazolam is a novel ultrashort-acting benzodiazepine characterized by rapid onset, predictable offset, and reversibility with flumazenil. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial
• The remimazolam induction dose is specified at 0.1 mg/kg bolus per the Japanese package insert, which pharmacodynamic studies show produces a shorter time to loss of responsiveness than continuous-infusion induction. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial
• A prior ERCP study found hypoxaemia in 9.6% of remimazolam patients compared to 15.7% of propofol patients, a statistically significant difference. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial
• A meta-analysis of upper gastrointestinal endoscopy found remimazolam associated with significantly lower hypoxaemia incidence but also significantly lower overall procedural success rate compared to propofol. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial
• In subgroup analyses restricted to elderly patients from a prior meta-analysis, procedural success did not differ significantly between remimazolam and propofol. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial
• Several studies have suggested that remimazolam causes less respiratory depression than propofol. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial
• Some data indicate remimazolam has a lower procedural success rate than propofol, and the overall evidence base remains limited. — Comparison of remimazolam versus propofol under deep sedation for elderly patients during prostate biopsy: a protocol for a randomised controlled trial